Matinas BioPharma Holdings Inc at Jefferies Healthcare Conference (Virtual) Transcript
It's an honor to have an 8 a.m. slot. Essentially, we're kicking off the conference. And certainly, this year's conference looks different than it has in years past. But hopefully, the updates we give you today about our company and the exciting work that we're doing, gives you some confidence going into the second half of this year.
I will be making some forward-looking statements over the course of the presentation so I would encourage everyone to do their diligence, and I would refer to our SEC filings. 25 minutes is a very short time for us to be able to capture everything that's going on within Matinas. And most of you who are tuning in today know what we're doing, know what we're all about and that we're focused essentially on 2 key lead assets: our MAT9001 and next year (inaudible); and then MAT2203, a novel oral formulation of amphotericin B supported by our platform.
The last few months have been a time of uncertainty, and certainly where our lives have been disrupted. But our team
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
